Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KW-6500 Long-Term Safety in Parkinson's Disease
NCT00955318Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Jul 2009
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apomorphine in Parkinson's disease (PD), sponsored by Kyowa Kirin. Primary endpoints: Incidence of adverse events at 52 weeks, Time to expression of the ON state at 52 weeks and 4 more. Started Jul 2009; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00955318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00955318.